(Q82405020)
Statements
Neutralizing antibodies, MxA expression and MMP-9/TIMP-1 ratio as markers of bioavailability of interferon-beta treatment in multiple sclerosis patients: a two-year follow-up study (English)
V de las Heras
M Bartolome
A Garcia-Martinez
27 December 2009